RadNet, Inc. (NASDAQ:RDNT) Given Average Rating of “Hold” by Analysts

Shares of RadNet, Inc. (NASDAQ:RDNTGet Rating) have been assigned an average recommendation of “Hold” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $39.50.

A number of research analysts have recently issued reports on RDNT shares. TheStreet cut RadNet from a “b-” rating to a “c” rating in a research note on Tuesday, March 15th. Zacks Investment Research cut RadNet from a “hold” rating to a “sell” rating in a research note on Friday, March 4th. Finally, StockNews.com began coverage on RadNet in a research note on Thursday, March 31st. They issued a “hold” rating on the stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Louisiana State Employees Retirement System lifted its holdings in RadNet by 5.6% in the first quarter. Louisiana State Employees Retirement System now owns 22,700 shares of the medical research company’s stock worth $485,000 after buying an additional 1,200 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in RadNet by 4.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 17,628 shares of the medical research company’s stock worth $394,000 after buying an additional 800 shares during the period. State of Alaska Department of Revenue lifted its holdings in RadNet by 3.3% in the first quarter. State of Alaska Department of Revenue now owns 32,433 shares of the medical research company’s stock worth $725,000 after buying an additional 1,030 shares during the period. Maryland State Retirement & Pension System lifted its holdings in RadNet by 5.7% in the first quarter. Maryland State Retirement & Pension System now owns 18,694 shares of the medical research company’s stock worth $418,000 after buying an additional 1,012 shares during the period. Finally, Norges Bank purchased a new position in shares of RadNet during the fourth quarter valued at approximately $1,093,000. Institutional investors and hedge funds own 68.74% of the company’s stock.

Shares of NASDAQ:RDNT opened at $20.08 on Friday. The stock’s 50-day moving average price is $22.24 and its 200-day moving average price is $26.30. RadNet has a 12-month low of $19.95 and a 12-month high of $38.84. The stock has a market capitalization of $1.13 billion, a P/E ratio of 43.65 and a beta of 1.72. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 2.15.

RadNet (NASDAQ:RDNTGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The medical research company reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.06). RadNet had a net margin of 1.88% and a return on equity of 10.91%. The company had revenue of $333.15 million for the quarter, compared to the consensus estimate of $347.96 million. As a group, research analysts predict that RadNet will post 0.37 EPS for the current year.

About RadNet (Get Rating)

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Articles

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.